Aliases & Classifications for Glioblastoma Multiforme

MalaCards integrated aliases for Glioblastoma Multiforme:

Name: Glioblastoma Multiforme 12 76 55 15 73
Glioblastoma 44 73
Grade Iv Adult Astrocytic Tumor 12
Primary Glioblastoma Multiforme 12
Adult Glioblastoma Multiforme 12
Spongioblastoma Multiforme 12
Primary Glioblastoma 73
Adult Glioblastoma 73
Gbm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3068
MeSH 44 D005909

Summaries for Glioblastoma Multiforme

Disease Ontology : 12 An astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has material basis in abnormally proliferating cells derives from multiple cell types including astrocytes and oligondroctyes.

MalaCards based summary : Glioblastoma Multiforme, also known as glioblastoma, is related to giant cell glioblastoma and glioblastoma, and has symptoms including headache and seizures. An important gene associated with Glioblastoma Multiforme is MIR21 (MicroRNA 21
miR-21 was involved in mediating chemoresistance to VM-26 in glioblastoma cells. Suppression of miR-21 by specific antisense oligonucleotides in glioblastoma cells U373 MG led to enhanced cytotoxicities of VM-26 against U373 MG cells. We further identified and validated LRRFIP1, whose product is an inhibitor of NF-kappaB signaling, as a direct target gene of miR-21. Our findings suggest that miR-21 represents a promising target for therapeutic manipulation to increase the efficacy of chemotherapeutic agents in treating glioblastoma, a highly lethal type of cancer.), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Avastin and Gliadel Wafer have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Wikipedia : 76 Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins... more...

Related Diseases for Glioblastoma Multiforme

Diseases related to Glioblastoma Multiforme via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 195)
# Related Disease Score Top Affiliating Genes
1 giant cell glioblastoma 34.0 EGFR IDH1 MGMT PTEN TP53
2 glioblastoma 32.7 DMBT1 EGFR IDH1 MGMT MIR128-1 MIR137
3 grade iii astrocytoma 32.5 DMBT1 EGFR MGMT PDGFRA PTEN TP53
4 gliosarcoma 32.2 EGFR IDH1 MGMT PTEN TP53
5 pleomorphic xanthoastrocytoma 32.0 IDH1 MGMT TP53
6 pilocytic astrocytoma 31.8 IDH1 MGMT PTEN TP53
7 gliomatosis cerebri 31.7 EGFR IDH1 PTEN TP53
8 mixed glioma 31.6 IDH1 PDGFRA TP53
9 brain cancer 31.6 DMBT1 EGFR IDH1 MGMT PDGFRA PTEN
10 medulloblastoma 31.5 DMBT1 EGFR IDH1 MGMT PDGFRA PTEN
11 small cell carcinoma 31.5 EGFR PDGFRA PTEN TP53
12 oligodendroglioma 31.3 EGFR IDH1 MGMT PDGFRA PTEN TP53
13 pituitary adenoma 29.8 MIR128-1 MIR132 MIR149
14 glioma 29.0 DMBT1 EGFR IDH1 MIR21 MIR210 MIR221
15 leukemia, chronic lymphocytic 28.7 MIR132 MIR155 MIR21 MIR221 TP53
16 prostate cancer 28.4 EGFR MIR149 MIR21 MIR210 MIR221 MTOR
17 pancreatic cancer 28.0 EGFR MIR155 MIR21 MIR210 MIR221 MTOR
18 melanoma 26.9 MIR128-1 MIR137 MIR149 MIR185 MIR210 MIR221
19 lung cancer 25.9 EGFR MGMT MIR133B MIR137 MIR155 MIR185
20 breast cancer 25.8 EGFR IDH1 MIR128-1 MIR149 MIR155 MIR21
21 brain glioblastoma multiforme 12.4
22 glioma susceptibility 1 12.2
23 adult spinal cord glioblastoma multiforme 12.2
24 goodpasture syndrome 11.9
25 mismatch repair cancer syndrome 11.5
26 brain ependymoma 11.3 EGFR TP53
27 fibrillary astrocytoma 11.3 IDH1 MGMT TP53
28 brain stem glioma 11.2 EGFR IDH1 TP53
29 spinal cord astrocytoma 11.2 IDH1 MGMT TP53
30 brain glioma 11.2 EGFR MGMT TP53
31 li-fraumeni syndrome 11.2 EGFR IDH1 PTEN TP53
32 chordoma 11.2 EGFR PDGFRA PTEN TP53
33 gastrointestinal system cancer 11.2 EGFR PDGFRA PTEN TP53
34 intracranial chondrosarcoma 11.2 IDH1 TP53
35 endometrial adenocarcinoma 11.2 EGFR PTEN TP53
36 suppression of tumorigenicity 12 11.2 IDH1 PTEN TP53
37 estrogen-receptor positive breast cancer 11.2 EGFR MTOR TP53
38 melanoma, cutaneous malignant 1 11.2 MGMT PTEN TP53
39 female reproductive organ cancer 11.2 EGFR PTEN TP53
40 gastrointestinal stromal tumor 11.2 EGFR PDGFRA PTEN TP53
41 cell type cancer 11.2 EGFR IDH1 MGMT PTEN TP53
42 oral cavity cancer 11.2 EGFR PTEN TP53
43 cerebellar astrocytoma 11.1 IDH1 TP53
44 renal cell carcinoma, papillary, 1 11.1 MTOR PTEN TP53
45 adamantinoma of long bones 11.1 EGFR MGMT PTEN TP53
46 glioma susceptibility 2 11.1
47 glioma susceptibility 3 11.1
48 glioma susceptibility 9 11.1
49 glioblastoma classical subtype 11.1
50 glioblastoma proneural subtype 11.1

Graphical network of the top 20 diseases related to Glioblastoma Multiforme:



Diseases related to Glioblastoma Multiforme

Symptoms & Phenotypes for Glioblastoma Multiforme

UMLS symptoms related to Glioblastoma Multiforme:


headache, seizures

GenomeRNAi Phenotypes related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.02 EGFR MTOR
2 Decreased viability with paclitaxel GR00179-A-2 9.02 MTOR
3 Decreased viability with paclitaxel GR00179-A-3 9.02 EGFR MTOR

MGI Mouse Phenotypes related to Glioblastoma Multiforme:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 respiratory system MP:0005388 9.17 EGFR IDH1 MGMT MTOR PDGFRA PTEN

Drugs & Therapeutics for Glioblastoma Multiforme

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Avastin 18 49 BEVACIZUMAB Genentech July 2009
2
Gliadel Wafer 18 49 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997
3
Temodar 18 49 TEMOZOLOMIDE Schering-Plough August 1999

Drugs for Glioblastoma Multiforme (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 591)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
4 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable
5 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
8
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
9
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 10339178 498142 38904
10
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
11
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
12
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
13
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
14
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154-93-8 2578
15
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 13010-47-4 3950
16
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
17
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
18
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
19
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702
20
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 7553-56-2 807
21
Aminolevulinic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
22
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
23
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
24
Hydroxychloroquine Approved Phase 2, Phase 3,Phase 1 118-42-3 3652
25
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
26
chloroquine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 54-05-7 2719
27
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
28
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
29
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
31
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
32
Copper Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 7440-50-8 27099
33
Flucytosine Approved, Investigational Phase 2, Phase 3,Phase 1 2022-85-7 3366
34
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
35
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
36
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
37
Valproic Acid Approved, Investigational Phase 3,Phase 2,Phase 1 99-66-1 3121
38
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
39
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
40
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
41
Disulfiram Approved Phase 2, Phase 3,Phase 1,Early Phase 1 97-77-8 3117
42
Povidone Approved Phase 3 9003-39-8
43
Povidone-iodine Approved Phase 3 25655-41-8
44
Dopamine Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
45
Angiotensin II Approved, Investigational Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
46
Losartan Approved Phase 3 114798-26-4 3961
47
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 5281106 54677470
48
Ephedrine Approved Phase 3 299-42-3 9294
49
Pseudoephedrine Approved Phase 3 90-82-4 7028
50
Norepinephrine Approved Phase 3 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 1335)
# Name Status NCT ID Phase Drugs
1 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
2 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
3 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
4 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
5 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
6 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
7 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
8 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
9 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
10 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
11 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3 Chloroquine
12 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
13 Nimotuzumab in Adults With Glioblastoma Multiforma Completed NCT00753246 Phase 3 nimotuzumab
14 Enzastaurin Versus Lomustine in Glioblastoma Completed NCT00295815 Phase 3 enzastaurin;lomustine
15 Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme Completed NCT00068952 Phase 3 Edotecarin;Temozolomide;Carmustine (BCNU);Lomustine (CCNU)
16 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
17 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
18 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3 temozolomide
19 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3 temozolomide
20 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3 Temozolomide
21 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Completed NCT00379470 Phase 3
22 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
23 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
24 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
25 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3 carmustine
26 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed NCT00777153 Phase 3 Cediranib;Cediranib;Lomustine Chemotherapy;Placebo Cediranib
27 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
28 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
29 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3 Temozolomide;Semustine
30 Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors Completed NCT00088400 Phase 3 TransMID
31 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
32 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
33 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
34 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
35 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
36 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3 Temozolomide
37 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
38 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
39 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
40 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
41 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
42 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
43 Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme Recruiting NCT02685605 Phase 3 Temozolomide
44 Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy Recruiting NCT03548571 Phase 2, Phase 3 Adjuvant temozolomide
45 A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification ( Intellance1 ) Recruiting NCT02573324 Phase 3 Temozolomide;ABT-414;Placebo for ABT-414
46 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects Recruiting NCT03393000 Phase 3 Trans Sodium Crocetinate plus SOC
47 Disulfiram in Recurrent Glioblastoma Recruiting NCT02678975 Phase 2, Phase 3 Disulfiram;Alkylating Agents
48 Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III Recruiting NCT02761070 Phase 3 Temozolomide;Bevacizumab
49 The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Recruiting NCT02414165 Phase 2, Phase 3 Toca FC;Lomustine;Temozolomide
50 Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME) Recruiting NCT03291977 Phase 3 Fluorescéine Sodique Faure

Search NIH Clinical Center for Glioblastoma Multiforme

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: glioblastoma

Genetic Tests for Glioblastoma Multiforme

Anatomical Context for Glioblastoma Multiforme

MalaCards organs/tissues related to Glioblastoma Multiforme:

41
Brain, T Cells, Endothelial, Testes, Bone, Bone Marrow, Lung

Publications for Glioblastoma Multiforme

Articles related to Glioblastoma Multiforme:

(show top 50) (show all 876)
# Title Authors Year
1
Glioblastoma multiforme subterfuge as acute cerebral hemorrhage: A case report and literature review. ( 29844891 )
2018
2
Evaluation of the relationship of erythrocyte membrane Na+/K+-ATPase enzyme activity and tumor response to chemoradiotherapy in patients diagnosed with locally advanced nonsmall cell lung cancer and glioblastoma multiforme. ( 29970705 )
2018
3
Benzyl isothiocyanate inhibits human brain glioblastoma multiforme GBM 8401 cell xenograft tumor in nude mice in vivo. ( 29972272 )
2018
4
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial. ( 29979390 )
2018
5
Venous thromboembolic complications with and without intermittent intraoperative and postoperative pneumatic compression in patients with glioblastoma multiforme using intraoperative magnetic resonance imaging. A retrospective study. ( 29859696 )
2018
6
Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models. ( 29385725 )
2018
7
Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profiles. ( 29963263 )
2018
8
microRNAa89574 inhibits cell proliferation and invasion in glioblastoma multiforme by directly targeting zinc finger Ea89boxa89binding homeobox 1. ( 29901177 )
2018
9
Specifically Targeted Electromagnetic Fields Arrest Proliferation of Glioblastoma Multiforme U-87 Cells in Culture. ( 29848672 )
2018
10
A case of subgaleal metastasis from glioblastoma multiforme. ( 29898273 )
2018
11
Does radiation therapy increase gadolinium accumulation in the brain?: Quantitative analysis of T1 shortening using R1 relaxometry in glioblastoma multiforme patients. ( 29444157 )
2018
12
Mutant cytoskeletal and ECM peptides sensitive to the ST14 protease are associated with a worse outcome for glioblastoma multiforme. ( 29953855 )
2018
13
Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients. ( 29899827 )
2018
14
Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells. ( 29416731 )
2018
15
Hyaluronic Acid-Modified Micelles Encapsulating Gem-C<sub>12</sub>and HNK for Glioblastoma Multiforme Chemotherapy. ( 29397747 )
2018
16
Early candidate biomarkers found from urine of glioblastoma multiforme rat before changes in MRI. ( 29372508 )
2018
17
Enhanced radiosensitization of human glioblastoma multiforme cells with phosphorylated peptides derived from Gli2. ( 29880393 )
2018
18
Semantic imaging features predict disease progression and survival in glioblastoma multiforme patients. ( 29442128 )
2018
19
Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment. ( 29387965 )
2018
20
A Rare Case of Concurrent Herpes Simplex Encephalitis and Glioblastoma Multiforme. ( 29492128 )
2018
21
Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience. ( 29889468 )
2018
22
Glioblastoma multiforme: another potential application for<sup>68</sup>Ga-PSMA PET/CT as a guide for targeted therapy. ( 29387926 )
2018
23
Reactive Astrocytes in Glioblastoma Multiforme. ( 29363044 )
2018
24
Longevity-Related Gene Transcriptomic Signature in Glioblastoma Multiforme. ( 29849920 )
2018
25
ATM and p53 combined analysis predicts survival in glioblastoma multiforme patients: a clinicopathologic study. ( 29369420 )
2018
26
Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the <i>SGK1</i> Gene Are Associated with Poorer Survival. ( 29976632 )
2018
27
Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy. ( 29378529 )
2018
28
High expression of a novel splicing variant of VEGF, L-VEGF144 in glioblastoma multiforme is associated with a poorer prognosis in bevacizumab treatment. ( 29909500 )
2018
29
Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. ( 29910795 )
2018
30
CircSMARCA5 Inhibits Migration of Glioblastoma Multiforme Cells by Regulating a Molecular Axis Involving Splicing Factors SRSF1/SRSF3/PTB. ( 29415469 )
2018
31
A Non-randomized Controlled Trial of EMDR on Affective Symptoms in Patients With Glioblastoma Multiforme. ( 29892240 )
2018
32
Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme. ( 29393542 )
2018
33
Management of Elderly patients with Glioblastoma - Multiforme. ( 29376741 )
2018
34
Cancer stem cells from peritumoral tissue of glioblastoma multiforme: the possible missing link between tumor development and progression. ( 29963265 )
2018
35
Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme. ( 29952031 )
2018
36
New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in Vitro. ( 29890725 )
2018
37
Development of an exercise intervention as part of rehabilitation in a glioblastoma multiforme survivor during irradiation treatment: a case report. ( 29382243 )
2018
38
Stereotactic Radiosurgery in the Multimodality Management of Residual or Recurrent Glioblastoma Multiforme. ( 29393176 )
2018
39
New aspects of glioblastoma multiforme revealed by similarities between neural and glioblastoma stem cells. ( 29383547 )
2018
40
Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming. ( 28785061 )
2017
41
Natural Bioactive Compounds: Alternative Approach to the Treatment of Glioblastoma Multiforme. ( 29359162 )
2017
42
Differentiation between progression and pseudoprogresion by arterial spin labeling MRI in patients with glioblastoma multiforme. ( 28952228 )
2017
43
MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor. ( 28501897 )
2017
44
Biomarkers and therapeutic advances in glioblastoma multiforme. ( 28840962 )
2017
45
Re-irradiation for recurrent glioblastoma multiforme. ( 28841798 )
2017
46
Role of Intra-operative MRI (iMRI) in Improving Extent of Resection and Survival in Patients with Glioblastoma Multiforme. ( 28770902 )
2017
47
A 4-miRNAs signature predicts survival in glioblastoma multiforme patients. ( 28869437 )
2017
48
MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. ( 28187000 )
2017
49
MiR-429 suppresses glioblastoma multiforme by targeting SOX2. ( 28749077 )
2017
50
A continuous-infusion dynamic MRI model at 3.0 Tesla for the serial quantitative evaluation of microvascular proliferation in an animal model of glioblastoma multiforme. ( 28078795 )
2017

Variations for Glioblastoma Multiforme

Copy number variations for Glioblastoma Multiforme from CNVD:

7 (show top 50) (show all 760)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13315 1 1 117600000 Gain Glioblastoma multiforme
2 13333 1 1 124300000 Gain Glioblastoma multiforme
3 13339 1 1 124300000 Loss Glioblastoma multiforme
4 13340 1 1 124300000 Loss Glioblastoma multiforme
5 13341 1 1 124300000 Loss Glioblastoma multiforme
6 13359 1 1 12600000 Gain Glioblastoma multiforme
7 13365 1 1 16100000 Gain Glioblastoma multiforme
8 13750 1 1 27800000 Loss Glioblastoma multiforme
9 13761 1 1 28000000 Deletion Glioblastoma multiforme
10 13763 1 1 28000000 Gain Glioblastoma multiforme
11 13775 1 1 39600000 Loss Glioblastoma multiforme
12 13792 1 1 51300000 Loss Glioblastoma multiforme
13 13822 1 1 7200000 Deletion MTHFR Glioblastoma multiforme
14 14314 1 107000000 111600000 Gain Glioblastoma multiforme
15 14414 1 107915304 108309068 amplification VAV3 Glioblastoma multiforme
16 14609 1 109636509 109651136 Fusion MYBPHL Glioblastoma multiforme
17 15403 1 115061059 115084034 Fusion CSDE1 Glioblastoma multiforme
18 16435 1 124300000 247249719 Gain Glioblastoma multiforme
19 16436 1 124300000 247249719 Gain Glioblastoma multiforme
20 16437 1 124300000 247249719 Gain Glioblastoma multiforme
21 16444 1 124300000 247249719 Loss Glioblastoma multiforme
22 16683 1 130300000 212100000 Gain ATP2B4 Glioblastoma multiforme
23 19008 1 148161834 148166860 Copy number SF3B4 Glioblastoma multiforme
24 19791 1 151370387 155734861 Gain CLK2 Glioblastoma multiforme
25 20600 1 153272923 153289968 Fusion DCST1 Glioblastoma multiforme
26 20612 1 153300000 154800000 Gain RAB25 Glioblastoma multiforme
27 21114 1 156847119 156923130 Copy number SPTA1 Glioblastoma multiforme
28 22041 1 16450831 16482564 Copy number EPHA2 Glioblastoma multiforme
29 23682 1 172900000 185800000 Gain Glioblastoma multiforme
30 24288 1 178190530 178346919 Fusion CEP350 Glioblastoma multiforme
31 25428 1 189000000 197500000 Gain Glioblastoma multiforme
32 25567 1 191357783 191486465 Fusion CDC73 Glioblastoma multiforme
33 26137 1 197500000 205300000 Amplification LRRN5 Glioblastoma multiforme
34 26138 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
35 26139 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
36 26142 1 197500000 205300000 Amplification NFASC Glioblastoma multiforme
37 26146 1 197500000 205300000 Amplificationlication HDMX Glioblastoma multiforme
38 26474 1 200429740 200554958 Truncation LGR6 Glioblastoma multiforme
39 26515 1 200858000 202110000 Copy number MDM4 Glioblastoma multiforme
40 26660 1 201942811 203355851 Amplification MDM4 Glioblastoma multiforme
41 28554 1 223214607 229308654 Gain ARF1 Glioblastoma multiforme
42 28555 1 223214607 229308654 Gain WNT3A Glioblastoma multiforme
43 29626 1 233890968 234060340 Fusion LYST Glioblastoma multiforme
44 30289 1 241700000 247249719 Amplification AKT3 Glioblastoma multiforme
45 30407 1 2429834 2447886 Fusion PANK4 Glioblastoma multiforme
46 31747 1 30500000 171200000 Gain Glioblastoma multiforme
47 32775 1 3928417 3978407 Deletion Glioblastoma multiforme
48 32899 1 4028404 6333694 Deletion AJAP1 Glioblastoma multiforme
49 32900 1 4028404 6333694 Deletion CHD5 Glioblastoma multiforme
50 33876 1 4952248 20897624 Deletion CDC42 Glioblastoma multiforme

Expression for Glioblastoma Multiforme

Search GEO for disease gene expression data for Glioblastoma Multiforme.

Pathways for Glioblastoma Multiforme

Pathways related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.73 EGFR MTOR PDGFRA PTEN TP53
2 12.69 EGFR MTOR PDGFRA PTEN TP53
3
Show member pathways
12.59 EGFR MTOR PDGFRA PTEN TP53
4
Show member pathways
12.55 EGFR MTOR PDGFRA PTEN TP53
5
Show member pathways
12.3 EGFR MTOR PDGFRA TP53
6
Show member pathways
12.21 MIR210 MIR221 PTEN TP53
7
Show member pathways
12.18 EGFR MTOR PDGFRA PTEN TP53
8 12.1 EGFR MIR21 MTOR TP53
9
Show member pathways
11.91 EGFR MTOR PDGFRA
10 11.89 EGFR MTOR PTEN TP53
11 11.88 EGFR MIR128-1 MIR133B MIR137 MIR155 MIR21
12 11.81 EGFR MTOR PDGFRA PTEN TP53
13 11.79 MTOR PTEN TP53
14
Show member pathways
11.75 EGFR MTOR TP53
15 11.68 EGFR MGMT MTOR PDGFRA PTEN TP53
16 11.66 MTOR PTEN TP53
17 11.34 EGFR PDGFRA TP53
18 11.31 MIR210 MIR221 TP53
19 11.25 EGFR IDH1 MTOR PDGFRA PTEN TP53
20 11.12 MIR128-1 MIR133B MIR221

GO Terms for Glioblastoma Multiforme

Cellular components related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 DMBT1 EGFR MIR128-1 MIR132 MIR155 MIR185
2 PML body GO:0016605 9.13 MTOR PTEN TP53

Biological processes related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.95 MIR137 MIR21 MIR221 PTEN TP53
2 positive regulation of gene expression GO:0010628 9.88 MIR132 MIR155 MIR21 MTOR PTEN TP53
3 negative regulation of apoptotic process GO:0043066 9.87 EGFR MGMT MIR21 MIR221 PDGFRA PTEN
4 positive regulation of protein phosphorylation GO:0001934 9.86 EGFR MIR128-1 MIR21 MTOR
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 EGFR MIR21 MIR221 PDGFRA PTEN
6 wound healing GO:0042060 9.81 EGFR MTOR PDGFRA
7 response to organic cyclic compound GO:0014070 9.8 EGFR IDH1 MGMT